



SHAREABLE PDF

A clinically significant bronchodilator response in children: how should it be measured?

Carmen C.M. de Jong ¹, Eva S.L. Pedersen¹, R. Mozun ¹, Myrofora Goutaki ^{1,2}, Daniel Trachsel³, Juerg Barben⁴ and Claudia E. Kuehni ^{1,2}

Affiliations: ¹Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. ²Paediatric Respiratory Medicine, Children's University Hospital of Bern, University of Bern, Bern, Switzerland. ³Paediatric Respiratory Medicine, Children's University Hospital of Basel, Basel, Switzerland. ⁴Paediatric Respiratory Medicine, Children's Hospital of Eastern Switzerland, St Gallen, Switzerland.

Correspondence: Claudia E. Kuehni, University of Bern, Institute of Social and Preventive Medicine, Mittelstrasse 43, CH-3012 Bern, Switzerland. E-mail: claudia.kuehni@ispm.unibe.ch



@ERSpublications

More research is needed to evaluate the usefulness of diagnostic tests for asthma in children and cut-offs should be critically questioned and defined based on evidence from the patient population of interest <https://bit.ly/33xjLVW>

Cite this article as: de Jong CCM, Pedersen ESL, Mozun R, *et al.* A clinically significant bronchodilator response in children: how should it be measured?. *Eur Respir J* 2020; 55: 2000636 [<https://doi.org/10.1183/13993003.00636-2020>].

This single-page version can be shared freely online.

From the authors:

We thank F. Guezguez and H. Ben Saad for raising important questions on recommendations for assessing a bronchodilator response (BDR) in children. The authors summarise how recommended outcome measures and cut-offs for BDR in children vary between guidelines, and raise questions about our study [1].